Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)-Reference-Cited by-同舟云学术

Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)

Published:2016-01-06 Issue:1 Volume:14 Page:
ISSN:1477-7827
Container-title:Reproductive Biology and Endocrinology
language:en
Short-container-title:Reprod Biol Endocrinol

Author:

Strowitzki Thomas,Kuczynski Waldemar,Mueller Arnd,Bias Peter

Funder

Medical writing assistance was provided by MedVal Scientific Information Services, LLC (Skillman, NJ), and was funded by Teva Branded Pharmaceutical Products R&D, Inc. (Frazer, PA).

Publisher

Springer Science and Business Media LLC

Subject

Developmental Biology,Endocrinology,Reproductive Medicine,Obstetrics and Gynecology

Link

http://link.springer.com/content/pdf/10.1186/s12958-015-0135-8

Reference27 articles.

1. De Leo V, Musacchio MC, Di Sabatino A, Tosti C, Morgante G, Petraglia F. Present and future of recombinant gonadotropins in reproductive medicine. Curr Pharm Biotechnol. 2012;13:379–91.

2. Leao RB, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics. 2014;69:279–93.

3. Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3:161–71.

4. Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report. Gynecol Endocrinol. 2000;14:149–52.

5. Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH). London, UK: European Medicines Agency; 2011.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative assessment of the DNA damage caused in cumulus cells by Corneumon®, Gonal-F®, Pergoveris® and Puregon® in women undergoing assisted reproduction techniques, and its impact on reproductive outcomes;2023-07-21

2. Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial;Reproductive BioMedicine Online;2023-03

3. Use of gonadotropins in ovarian stimulation in Spain: Delphi consensus;Journal of Obstetrics and Gynaecology;2023-02-11

4. Clinical outcomes in patients receiving originator follitropin alfa and follitropin alfa biosimilars in real-world clinical practice: A retrospective study;Journal of Human Reproductive Sciences;2023

5. An updated meta-analysis comparing the efficacy and safety of biosimilar medicinal products to the original follitropin alfa;Minerva Obstetrics and Gynecology;2022-12